Business
PDS Biotech Provides Business Update and Reports Second Quarter 2021 Financial Results
FLORHAM PARK, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel
About this update from Pds Biotechnology Corporation
[{"type":"text","content":"FLORHAM PARK, N.J., Aug. 12, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, will discuss its financial results for the quarter ended June 30, 2021 and provide a business update on its conference call today. Recent Business Highlights: Presented interim Phase 2 clinical data for lead product PDS0101, in an oral presentation at the American Society for Clinical Oncology (ASCO) 2021 Annual Meeting. In the National Cancer Institute-led study, tumor reduction was observed in 83% (5 of 6) of advanced HPV16-positive cancer patients who had relapsed or failed treatment with chemotherapy and radiation but had not been treated with checkpoint inhibitor therapy. Tumor reduction was reported in 58% (7 of 12) of HPV16-positive patients who in addition had also failed checkpoint inhibitor therapy.Completed approximately $52 Million public offering that will support next phase of company growth through advancement of PDS0102 and PDS0103 into human clinical trials.Received $4.5 Million from the sale of Net Operating Loss tax benefits through the New Jersey Economic Development Program.Appointed immuno-oncology experts Dr. Olivera Finn and Dr. Mark Frohlich to Scientific Advisory Board.Expanded VERSATILE-002 study of PDS0101 and KEYTRUDA® in advanced head and neck cancer to include patients who have failed prior treatment with checkpoint inhibitors.Added to Russell Microcap® Index as part of the 2021 annual reconstitution based on market-capitalization rankings and style attributes. “The second quarter has been quite significant for PDS Biotech in providing the first demonstration of the clinical potential of the Versamune®-based products in treating advanced, treatment-resistant cancers. We believe the unprecedented objective responses and tumor reduction observed in our most advanced PDS0101 phase 2 clinical trial demonstrate the potential of the Versamune® platform to overcome one of the most significant limitations preventing broadly effective cancer immunotherapy. Versamune® has the potential to induce high levels of potent tumor-specific killer T-cells that may attack and eliminate the cancer,” commented Dr. Frank Bedu-Addo, President and Chief Executive Officer of PDS ...